KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Gross Margin: 2010-2023

Historic Gross Margin for TherapeuticsMD (TXMD) over the last 14 years, with Dec 2023 value amounting to 100.00%.

  • TherapeuticsMD's Gross Margin changed negligibly% to 100.00% in Q4 2023 from the same period last year, while for Dec 2023 it was 92.47%, marking a year-over-year decrease of 7491.00%. This contributed to the annual value of 100.00% for FY2023, which is 200.00% up from last year.
  • Latest data reveals that TherapeuticsMD reported Gross Margin of 100.00% as of FY2023, which was up 2.04% from 98.00% recorded in FY2022.
  • TherapeuticsMD's Gross Margin's 5-year high stood at 100.00% during FY2023, with a 5-year trough of 45.51% in FY2021.
  • Its 3-year average for Gross Margin is 81.17%, with a median of 98.00% in 2022.
  • As far as peak fluctuations go, TherapeuticsMD's Gross Margin slumped by 2,986bps in 2021, and later skyrocketed by 5,249bps in 2022.
  • TherapeuticsMD's Gross Margin (Yearly) stood at 87.24% in 2019, then slumped by 1,187bps to 75.37% in 2020, then crashed by 2,986bps to 45.51% in 2021, then surged by 5,249bps to 98.00% in 2022, then spiked by 200bps to 100.00% in 2023.